[go: up one dir, main page]

MX2010005036A - Formulaciones de polvo seco que comprenden derivados del acido ascorbico. - Google Patents

Formulaciones de polvo seco que comprenden derivados del acido ascorbico.

Info

Publication number
MX2010005036A
MX2010005036A MX2010005036A MX2010005036A MX2010005036A MX 2010005036 A MX2010005036 A MX 2010005036A MX 2010005036 A MX2010005036 A MX 2010005036A MX 2010005036 A MX2010005036 A MX 2010005036A MX 2010005036 A MX2010005036 A MX 2010005036A
Authority
MX
Mexico
Prior art keywords
dry powder
ascorbic acid
powder formulations
acid derivates
derivates
Prior art date
Application number
MX2010005036A
Other languages
English (en)
Inventor
Jan Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010005036A publication Critical patent/MX2010005036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona formulaciones farmacéuticas de polvo seco comprenden un derivado del ácido ascórbico que presenta un comportamiento inhalatorio bueno e inhaladores de polvo seco que las contienen.
MX2010005036A 2007-11-07 2008-11-06 Formulaciones de polvo seco que comprenden derivados del acido ascorbico. MX2010005036A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98602607P 2007-11-07 2007-11-07
US7344308P 2008-06-18 2008-06-18
PCT/SE2008/051265 WO2009061273A1 (en) 2007-11-07 2008-11-06 Dry powder formulations comprising ascorbic acid derivates

Publications (1)

Publication Number Publication Date
MX2010005036A true MX2010005036A (es) 2010-05-27

Family

ID=40626004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005036A MX2010005036A (es) 2007-11-07 2008-11-06 Formulaciones de polvo seco que comprenden derivados del acido ascorbico.

Country Status (17)

Country Link
US (1) US20110105449A1 (es)
EP (1) EP2217278A1 (es)
JP (1) JP2011503058A (es)
KR (1) KR20100095437A (es)
CN (1) CN101909652A (es)
AU (1) AU2008325290B2 (es)
BR (1) BRPI0819259A2 (es)
CA (1) CA2704639A1 (es)
CO (1) CO6270343A2 (es)
CR (1) CR11419A (es)
DO (1) DOP2010000138A (es)
EA (1) EA201000677A1 (es)
EC (1) ECSP10010164A (es)
IL (1) IL205514A0 (es)
MX (1) MX2010005036A (es)
WO (1) WO2009061273A1 (es)
ZA (1) ZA201003223B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011120779A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
CN102302488A (zh) * 2011-07-06 2012-01-04 中山大学 一种针对ccl18靶标的化合物在制备抗乳腺癌药物中的应用
WO2014007773A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and sorbitol
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
JP5087182B1 (ja) 2012-06-13 2012-11-28 クリニプロ株式会社 吸入用パウダーの製造方法
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
CN106604720B (zh) 2014-09-09 2020-03-10 维克多瑞有限公司 包含格隆铵的制剂、方法和设备
EP3277265A1 (en) * 2015-04-01 2018-02-07 Lupin Atlantis Holdings SA Process for manufacturing dry powder blends

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071963A (en) * 1996-11-06 2000-06-06 Roche Vitamins Inc. Water dispersible compositions
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
CA2424021A1 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine compositions and uses thereof
US20020085978A1 (en) * 2000-11-10 2002-07-04 Mina Buenafe Degradation-resistant glucocorticosteroid formulations
US20020165207A1 (en) * 2001-05-02 2002-11-07 Richard Rosenbloom Compositions and methods for the treatment of diabetic neuropathy
KR20120089705A (ko) * 2004-04-23 2012-08-13 사이덱스 파마슈티칼스, 인크. 술포알킬 에테르 시클로덱스트린 함유 ｄｐｉ 제형
CA2591406A1 (en) * 2004-12-17 2006-06-22 Cipla Limited Pharmaceutical compounds and compositions

Also Published As

Publication number Publication date
CN101909652A (zh) 2010-12-08
US20110105449A1 (en) 2011-05-05
EP2217278A1 (en) 2010-08-18
CA2704639A1 (en) 2009-05-14
KR20100095437A (ko) 2010-08-30
WO2009061273A1 (en) 2009-05-14
AU2008325290B2 (en) 2011-12-08
EA201000677A1 (ru) 2010-12-30
ECSP10010164A (es) 2010-06-29
IL205514A0 (en) 2010-12-30
DOP2010000138A (es) 2010-06-15
BRPI0819259A2 (pt) 2019-10-01
CR11419A (es) 2010-08-27
JP2011503058A (ja) 2011-01-27
CO6270343A2 (es) 2011-04-20
ZA201003223B (en) 2011-04-28
AU2008325290A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
MX2010005036A (es) Formulaciones de polvo seco que comprenden derivados del acido ascorbico.
EG25313A (en) Improved dry powder inhaler.
CA2865972C (en) Inhalable dry powders
GB2439204B (en) Dry powder inhalers
WO2009008001A3 (en) Inhalation device
IL179488A0 (en) Dry powder inhaler
IL189737A0 (en) Pyrazine derivatives, their preparation and pharmaceutical compositions containing them
PL2010258T3 (pl) Inhalator suchego proszku
IL200206A0 (en) Quinoxaline darivatives, their preparation and pharmaceutical compositions containing them
MX2013000567A (es) Composiciones farmaceuticas de moduladores de c-met.
IL188050A (en) The history of azaindazole, their medicinal preparations and their uses
IL221103A0 (en) Inhaler powdered, particularly medical substances
GB0804716D0 (en) Dry powder inhalers
HK1244819A1 (zh) Foxm1肽和包含foxm1肽的藥劑
IL204844A (en) Coinolone analogues, pharmaceuticals containing them and their uses
EP2220081A4 (en) GLUCCOAINEACTIVATORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE SUBSTANCES
EP2015740A4 (en) NEW LOW-DOSED PHARMACEUTICAL COMPOSITIONS WITH NIMESULID, PREPARATION AND USE
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
EP2205301A4 (en) MEDICAL INHALATION DEVICES AND COMPONENTS THEREOF
EP2682101A3 (en) Inhalation Compositions Comprising Glucose Anhydrous
WO2010046061A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
MX2009012370A (es) Formulacion de antraciclina de baja viscosidad.
WO2014007781A3 (en) Inhalation compositions
IL186805A0 (en) Pharmaceutical compositions containing an active vitamin d compound

Legal Events

Date Code Title Description
FA Abandonment or withdrawal